202-cov
Vaccineexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 12, 2021 (NCT04982068)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05490108 | Phase 1/Phase 2 (Phase 2) | Jun 2, 2022 | Center for Vaccine Development CVD-Mali, Shanghai Zerun Biotechnology Co.,Ltd |
| NCT05313022 | Phase 1/Phase 2 (Phase 2) | Jan 18, 2022 | Shanghai Zerun Biotechnology Co.,Ltd, Walvax Biotechnology Co., Ltd. |
| NCT04990544 | Phase 2 | Jul 31, 2021 | Shanghai Zerun Biotechnology Co.,Ltd, Walvax Biotechnology Co., Ltd. |
| NCT04982068 | Phase 1 | Jul 12, 2021 | Shanghai Zerun Biotechnology Co.,Ltd, Walvax Biotechnology Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Zerun Biotechnology Co.,Ltd | For profit | 4 | 4 | 2 | 2021 |
| Walvax Biotechnology Co., Ltd. | For profit | 3 | 0 | 2 | 2021 |
| Center for Vaccine Development CVD-Mali | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1